Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 21, 2026
TickeronGET DAILY SIGNALS
Rapport Therapeutics (RAPP) Shares Decline -34% in 30 Days on Bipolar Mania Readout

Rapport Therapeutics (RAPP) Shares Decline -34% in 30 Days on Bipolar Mania Readout

Key Takeaways

  • RAPP shares fell roughly 34% over the trailing 30 days, sliding from a closing price near $39.66 to approximately $26.
  • The decline accelerated after a late-September reset in expectations around the RAP-219 bipolar mania readout.
  • RAP-219 met its Phase 2 primary endpoint in bipolar mania, but the effect size landed below the "clinically meaningful" threshold management had previously cited, triggering a "sell the news" reaction.
  • The stock is also down about 38% from three months earlier, despite a strong focal-onset-seizure data set and an enrolling Phase 3 program.
  • A cash position of roughly $477 million at the end of the first quarter of 2026 and an expanding pipeline remain key offsets to near-term volatility.

Rapport Therapeutics (RAPP) Background and Positioning

Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Founded in 2022 and based in Boston, the company completed its initial public offering on the Nasdaq in June 2024. Its RAP technology platform is built on discoveries around receptor-associated proteins (RAPs) that are expressed only in discrete regions of the brain, an approach intended to improve efficacy while reducing the off-target side effects common to conventional neuroscience drugs.

The company's lead candidate, RAP-219, is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator. Because TARPγ8 is concentrated in the hippocampus and neocortex but minimally expressed in the hindbrain, Rapport positions RAP-219 as a "pipeline-in-a-product" with the potential to address focal onset seizures, primary generalized tonic-clonic seizures, bipolar mania, and other central nervous system conditions. Investors follow the stock closely because the readouts for RAP-219 across these indications could define a multi-billion-dollar commercial opportunity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Performance: 30 Days and the Quarter

Over the last 30 days, RAPP shares declined approximately 34%, moving from a close of about $39.66 on September 21 to near $26 in late-October trading. The move was not a single-day collapse but rather a steady de-risking punctuated by sharp sell-offs in late September and again around the October 20 bipolar mania readout.

The three-month picture is similar in direction but reflects more volatility. From a close of roughly $42.56 on July 21, the stock rallied to an intraday high near $52.50 in late August before giving back those gains. By late October the shares traded near $26, leaving the stock down approximately 38% over the quarter despite a strong Phase 2a epilepsy data set and a fully enrolled Phase 3 program. From what I see, the pattern shows how quickly sentiment can shift even with solid underlying progress.

Key Drivers Behind the 30-Day Decline

The sharpest single catalyst within the 30-day window was management commentary in late September. At a TD Cowen neuropsychiatry event, Chief Executive Officer Abraham Ceesay described a four-point placebo-adjusted improvement on the Young Mania Rating Scale (YMRS) as the "clinically meaningful threshold" for the bipolar mania program. That reference reset investor expectations and coincided with a steep one-day sell-off as traders reassessed the probability of a differentiated result.

The second major catalyst arrived on October 20, 2026, when Rapport reported topline results from its Phase 2 trial of RAP-219 in acute bipolar mania. The drug met its primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in YMRS total score at Week 3 (p=0.045) and also achieved a prespecified secondary endpoint. The therapy was well tolerated, with no severe treatment-emergent adverse events reported. However, the 3.1-point effect fell short of the four-point bar the company itself had flagged, and it sat at the low end of the three-to-four-point range historically delivered by approved therapies. Shares spiked in premarket trading before reversing sharply, a classic "sell the news" reaction driven by the modest magnitude of the effect rather than a clinical failure. One thing that stands out here is how the market weighed the statistical win against prior guidance.

Quarter-Long Factors Influencing RAPP

The quarter's broader narrative combines positive pipeline progress with profit-taking and pre-readout de-risking. In April 2026, follow-up data from the Phase 2a focal-onset-seizure trial presented at the American Academy of Neurology meeting showed a 90% median reduction in clinical seizures in the first four weeks after dosing ended, reinforcing confidence in the epilepsy program. Phase 3 FOCUS 1 and FOCUS 2 trials began enrolling in the second quarter.

That progress attracted constructive analyst coverage, including price-target increases from BTIG, Raymond James, and H.C. Wainwright, as well as new Buy initiations. The stock rallied to multi-month highs near $52.50 in late August. Yet a sizable insider sale by venture investor Third Rock Ventures, a second-quarter earnings miss, and a broader pullback in speculative biotech sentiment contributed to the subsequent decline. By late October, the optimism built around the bipolar mania readout had largely unwound as investors weighed a statistically positive but modestly sized result against elevated expectations. I reviewed recent patterns around similar events with Tickeron’s AI Real Time Patterns to put the moves in context.

Upcoming Catalysts for RAPP Investors

Looking ahead, the most important catalyst for RAPP is the progress of the FOCUS 1 and FOCUS 2 Phase 3 trials in focal onset seizures, which will ultimately determine whether RAP-219 can reach the market. Investors are also watching the planned FDA meeting in the first quarter of 2027 to discuss the registrational design for the bipolar mania program, with Phase 3 trials in that indication expected to begin in the second half of 2027.

Additional data catalysts include initial results from the open-label extension study in the second half of 2026, a Phase 3 program in primary generalized tonic-clonic seizures expected to begin in the first half of 2027, and initial pharmacokinetic results for a long-acting injectable formulation in 2027. Near-term quarterly earnings will also be closely watched, as will the company's ability to preserve its cash runway, which management has guided into the second half of 2029. As with all clinical-stage biotech companies, trial outcomes, regulatory decisions, and financing conditions carry meaningful risk.

AI Tools for Navigating Volatile Biotech Names

For traders who prefer a data-driven approach to navigating volatile names like RAPP, Tickeron’s Trending AI Robots page offers a curated view of AI-powered trading strategies. I find it useful to review the top-performing bots here when assessing how systematic signals align with fundamental developments in clinical-stage names. The section highlights bots with different strategies and timeframes, letting users match approaches to their own risk tolerance while staying grounded in recent performance data.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RAPP

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RAPP's Indicator enters downward trend

The Aroon Indicator for RAPP entered a downward trend on November 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 72 similar instances where the Aroon Indicator formed such a pattern. In 66 of the 72 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RAPP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RAPP's RSI Indicator exited the oversold zone, 4 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on RAPP as a result. In 44 of 47 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for RAPP just turned positive on October 19, 2026. Looking at past instances where RAPP's MACD turned positive, the stock continued to rise in 24 of 29 cases over the following month. The odds of a continued upward trend are 83%.

Following a +9.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where RAPP advanced for three days, in 124 of 140 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

RAPP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.773) is normal, around the industry mean (3.498). P/E Ratio (-8.066) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. RAPP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RAPP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
99 High Street
Phone
+1 857 321-8020
Employees
84
Web
https://www.rapportrx.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
EUO is a leveraged inverse currency fund targeting -2x the daily performance of the euro versus the U.S. dollar, while XXX is a passive asset-allocation fund blending roughly 75% S&P 500 equities with 25% XRP exposure. The two funds are structurally unrelated: EUO is a tactical hedging and trading tool, whereas XXX is a diversified, long-biased growth vehicle.